|
|
|
LifeScienceHistory.com - Check us out on Instagram
New York Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing New YorkLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Intercept Pharmaceuticals, Inc.
| | | Phone: | (858) 652-6800 | Fax: | (858) 558-5961 | Year Established: | 2002 | Ticker: | ICPT | Exchange: | NASDAQ | Main Contact: | Sandip Kapadia, CFO | | Other Contacts: | Christian Weyer, M.D., M.A.S., Executive VP, R&D Jerry Durso, COO Lisa Bright, Chief Commercial & Corporate Affairs Officer Rachel McMinn, Ph.D., Chief Strategy Officer David Shapiro, M.D.,, CMO Mark Pruzanski, M.D., Founder, President & CEO
| | Company Description | Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat orphan and more prevalent liver diseases utilizing its expertise in bile acid chemistry. The company's lead product candidate, obeticholic acid, or OCA, is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR). OCA is initially being developed for the second line treatment of primary biliary cirrhosis (PBC) in patients with an inadequate response to, or who are unable to tolerate, ursodiol, the only approved therapy for this indication. PBC is a chronic autoimmune liver disease that may progress to cirrhosis and liver failure, and it is currently the fifth leading indication for liver transplant in the United States. OCA has orphan drug designation in both the United States and Europe for the treatment of PBC. Intercept owns worldwide rights to OCA outside of Japan and China, where it has outlicensed the product candidate to Dainippon Sumitomo Pharma (DSP).
About INT- | |
|
|
|
|
|